Maternal Age Down Syndrome Risk

Female oocytes are formed during fetal development and remain arrested in meiosis I until ovulation — potentially for 40+ years. During this prolonged arrest, the spindle checkpoint mechanism that ensures accurate chromosome segregation becomes less reliable with age, increasing the probability of non-disjunction (failure to separate chromosome pairs correctly) and resulting in eggs with 24 instead of 23 chromosomes.

The maternal age effect is far more significant than paternal age for chromosomal trisomies, because most trisomies arise from meiotic errors in the oocyte. Advanced paternal age (>40 years) is associated with an increased risk of new (de novo) single-gene mutations causing conditions such as achondroplasia, Apert syndrome, and Noonan syndrome, but not primarily with chromosomal trisomies.

Combined first-trimester screening uses maternal age, NT ultrasound measurement, and serum biochemistry (PAPP-A and free beta-hCG) to generate a risk estimate; it is a screening test, not diagnostic. NIPT (non-invasive prenatal testing, also called cell-free DNA testing) analyses fragments of fetal DNA in maternal blood with very high sensitivity (>99%) and specificity for the common trisomies, making it a superior screening test. Neither is diagnostic — a definitive diagnosis requires CVS or amniocentesis.

First-trimester combined screening and NIPT are primarily designed to detect trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). Extended NIPT panels also screen for sex chromosome aneuploidies (Turner syndrome XO, Klinefelter syndrome XXY, Triple X, XYY) and some panels include detection of larger chromosomal deletions (microdeletions). None of these tests detect all birth defects.

The nuchal translucency (NT) is the fluid-filled space at the back of the fetal neck, measured by ultrasound at 11–13+6 weeks. A thickened NT (>95th percentile for crown-rump length, approximately 3.5 mm) is associated with chromosomal abnormalities (particularly trisomy 21), structural cardiac defects, and a range of other conditions. A normal NT does not exclude all abnormalities.

Modern data from experienced operators show the procedure-related risk of miscarriage for both CVS (at 11–14 weeks) and amniocentesis (at 15+ weeks) is approximately 0.1–0.5% per procedure, somewhat lower than historical estimates. CVS provides results 4 weeks earlier than amniocentesis, which is clinically significant for decision-making. CVS carries a small risk of confined placental mosaicism complicating interpretation.

IVF with preimplantation genetic testing for aneuploidy (PGT-A) screens embryos before transfer and selects euploid embryos, reducing the live birth risk of trisomy. However, PGT-A does not eliminate the risk entirely (mosaicism and false-negative results occur) and is primarily used in IVF patients with recurrent implantation failure or recurrent miscarriage, not as a routine risk-reduction strategy for older women conceiving naturally.

Prenatal screening is entirely voluntary. Women who decline should be counselled non-directively about the options available and the implications of declining. They should be offered a full structural ultrasound at the anomaly scan (20 weeks), where some chromosomal conditions and cardiac defects may be detected on fetal anatomy assessment, though sensitivity is lower than dedicated screening.